Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mercaptopurine
Drug ID BADD_D01392
Description An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Indications and Usage For remission induction and maintenance therapy of acute lymphatic leukemia.
Marketing Status Prescription
ATC Code L01BB02
DrugBank ID DB01033
KEGG ID D00161
MeSH ID D015122
PubChem ID 667490
TTD Drug ID D09UZO
NDC Product Code 60763-601; 69076-913; 15308-0712; 12780-0299; 62991-2899; 0378-3547; 0054-4581; 38779-1427
Synonyms Mercaptopurine | 6H-Purine-6-thione, 1,7-dihydro- | 6-Mercaptopurine Monohydrate | 6 Mercaptopurine Monohydrate | 6-Thiopurine | 6 Thiopurine | 1,7-Dihydro-6H-purine-6-thione | 6-Mercaptopurine | 6 Mercaptopurine | 6-Thiohypoxanthine | 6 Thiohypoxanthine | Purinethol | Puri-Nethol | Mercaptopurina Wellcome | Leupurin | BW 57-323H | BW 57 323H | BW 57323H | Purimethol | Mecaptopurine Anhydrous
Chemical Information
Molecular Formula C5H4N4S
CAS Registry Number 50-44-2
SMILES C1=NC2=C(N1)C(=S)N=CN2
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
ApoptosisNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
ArteriosclerosisNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
Bone marrow toxicityThiopurine S-methyltransferaseP51580Not Available15228171; 9893619; 12525681
InflammationNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
Nervous system disordersNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
Soft tissue neoplasms malignant and unspecifiedNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Non-Hodgkin's lymphoma16.35.01.001; 01.17.01.0010.002510%Not Available
Oedema08.01.07.006; 14.05.06.010--Not Available
Oligospermia21.03.03.005--
Oral candidiasis11.03.03.004; 07.05.07.001--Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.0100.009623%
Palpitations02.01.02.0030.003849%
Pancreatitis07.18.01.0010.034642%
Pancreatitis acute07.18.01.0020.015396%Not Available
Pancytopenia01.03.03.0030.013472%Not Available
Paraesthesia17.02.06.0050.007698%
Peripheral coldness24.04.03.006; 08.01.09.0100.005774%Not Available
Platelet count decreased13.01.04.0010.003849%
Pneumonia11.01.09.003; 22.07.01.003--Not Available
Portal hypertension24.08.06.001; 09.01.06.0060.021170%
Psoriasis23.03.14.002; 10.02.01.0360.005774%Not Available
Pulmonary granuloma22.01.01.0140.003849%Not Available
Pyrexia08.05.02.0030.034642%
Rash23.03.13.001--Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.0010.005774%
Sepsis11.01.11.0030.001004%
Septic shock24.06.02.011; 11.01.11.0040.001506%Not Available
Skin cancer23.08.02.002; 16.03.02.0020.005774%Not Available
Skin disorder23.03.03.007--Not Available
Skin hyperpigmentation23.05.01.003--
Small intestinal obstruction07.13.06.0010.007698%
Squamous cell carcinoma16.16.01.0020.003849%Not Available
Stomatitis07.05.06.0050.009623%
Stress19.06.02.0040.005774%Not Available
T-cell lymphoma16.17.02.001; 11.05.17.006; 01.11.02.0010.001506%Not Available
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages